ABMD - Abiomed beats top and bottom line; guides FY 2023 topline growth of 13-17%
- Abiomed press release ( NASDAQ: ABMD ): Q1 Non-GAAP EPS of $1.25 beats by $0.19 .
- Revenue of $277M (+9.7% Y/Y) beats by $0.54M .
- Worldwide product revenue of $264 million, an increase of 10%
- U.S. product revenue of $216 million, an increase of 9%.
- Outside the U.S. product revenue of $49 million, an increase of 11%.
- The company maintains its previous fiscal year 2023 global revenue guidance of 13% to 17% growth in constant currency. The company is also maintaining its fiscal year 2023 guidance for GAAP operating margin to be in the range of 23% to 24%. Based on current foreign exchange rates, the company now expects reported revenue of $1.13 to $1.17 billion or 10% to 14% growth compared to fiscal year 2022.
For further details see:
Abiomed beats top and bottom line; guides FY 2023 topline growth of 13-17%